Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
Dr Etienne Brain - Institut Curie, Paris, France
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer ( Dr Etienne Brain - Institut Curie, Paris, France )
6 Jun 2022
Dabrafenib plus trametinib significantly increases overall response rate in paed...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )
6 Jun 2022
Comment: Dabrafenib plus trametinib significantly increases overall response rat...
Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA
Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA )
6 Jun 2022
Dabrafenib plus trametinib significantly increases overall response rate in paed...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )
6 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )
5 Jun 2022
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
ASCO 2022: Latest in EGFR positive NSCLC ( Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip )
5 Jun 2022
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...
Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression ( Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre,  Manhattan, USA )
5 Jun 2022
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides be...
Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA )
5 Jun 2022
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...
Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA )
5 Jun 2022
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )
5 Jun 2022
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significanc...
Dr Julie Gralow- Chief Medical Officer, ASCO
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )
5 Jun 2022
Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosf...
Dr Julie Gralow- Chief Medical Officer, ASCO
Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )
5 Jun 2022